



ANNUAL GENERAL MEETING 13 NOVEMBER 2019

A. REGISTRAR'S ANNUAL REPORT 2019: Dr THOMAS MORRIS FFPM

I am pleased to present my fourth annual report to you as Registrar of FPM.

The Membership

As at October 2019 there were 1556 FPM members in 36 countries with 79% based within the United Kingdom and 21% based in other countries. This year we have seen a 0.8% increase in the net number of members since this time last year, reversing the small decline in membership numbers over the previous two years. There has been no change in the overall proportion of members based outside of the United Kingdom since this time last year.

The Board of Trustees

The Board of Trustees met on four occasions during the last twelve months with an average attendance of 84%, the same as last year. There are fourteen trustees in total including two lay trustees and three nominated by each of our three parent medical royal colleges. The remaining trustees are elected or appointed from the FPM membership. The Board of Trustees is responsible for the governance of FPM including setting its overall strategic direction and monitoring progress.

Committees

The work of FPM is conducted through committees. The operational committees comprise of:

- Education and Standards Committee
- Ethics and Practice Committee
- Policy and Communications Group
- Trainees' Committee
- Finance Committee

Chairpersons of the above committees together with the four Officers of FPM are members of the Coordination Committee.

A number of new appointments have been made for committee chairpersons and members, these will be announced at the AGM.

In 2019, the Strategic Oversight Committee (SOC) was established to help guide FPM during a period of intense change as FPM seeks to exploit opportunities to grow and increase revenue. The SOC will help to guide FPM during this time of great change as Pharmaceutical Medicine is becoming increasingly international, and its science and practice is advancing at a tremendous pace.

In addition to these standing committees, additional working groups are also established periodically on an as required basis to evaluate specific topics. A Governance and Regulation Committee was convened by the Board this year. The work of the committee on this occasion was focused on governance aspects and oversight arrangements surrounding the DHP exam. The committee will report to the Board with a description of its findings and a recommended plan of action or work to enhance governance procedures.

On behalf of FPM, I would like to thank all those FPM members who give so generously of their time and expertise to support our activities. Committee vacancies and other opportunities are posted on our website and most applications are open to Affiliate and Associate members as well as to Members and Fellows.

Fellowship and Awards 2019

This year, nineteen new Fellows were admitted by the Board following the recommendation of the Fellowship Committee. Fellowship of FPM is awarded in recognition of a Member's achievements and their contributions to the specialty and to FPM. In addition, twelve nominations for Honorary Fellowship and one nomination for Membership by Distinction were successful. Recognition and celebration of these achievements will take place at FPM's Awards Ceremony on the 13 November 2019 at the Royal College of Physicians. At the ceremony we will also recognise new Members and new Specialist Registrants. On behalf of FPM I offer my congratulations to all those who have received FPM awards during 2019.

Board Elections and Appointments 2019

During the last 12 months we held the appointment process for Treasurer and appointed Trustees as well as a call for an Elected Member post. The Appointments Panel was convened to oversee the appointment of the Treasurer and appointed Trustee and as a result

- Dr Tim Crook was appointed as the Treasurer
- Dr David Jefferys was appointed as a Fellow Trustee for a second term
- Dr Lalitha Mahadavan was co-opted as a Member Trustee

At this year's AGM the Treasurer, Dr Chris Worth, will stand down having completed two three-year terms of office. Dr Worth has made a substantial contribution to FPM and steered FPM to a financial position from which it can invest and expand.

On behalf of FPM I would like to record our great thanks to Dr Worth for the exceptional level of commitment he has brought to the role, particularly around prudence and the analytical thoroughness with which he has discharged his responsibilities. We wish him well for the future and hope he can continue contributing to FPM.

Also standing down are: Professor Matthew Walters, Parent College Trustee from RCP&S Glasgow. The Board of Trustees extends its thanks and appreciation to Professor Walters and we wish him well for the future.

FPM Headquarters

FPM has been at its new headquarters in Angel Gate, Islington, for four years now. I know that many members have had the opportunity to visit for meetings, events and, for some, revalidation appraisals. I would encourage you to take advantage of the members' room when you are in London and to hire one of our meeting rooms in connection with your day-to-day work or recommend this to colleagues. The members' room is available between 9am-5pm Monday to Friday with no pre-booking required.

FPM Staff

Finally, I would like to record my thanks on behalf of the FPM membership to the staff for their continuing hard work in managing and supporting FPM's very varied activities: Dr Marcia Philbin, Sarah Davis, Dr Ben Cottam, Katie Liversidge, Andrew Meads, Konrad Obiora, Will Strange and Marianne Whitlam.

Sam Hutchinson and Alina Dragomir left FPM this year, I would also like to thank them for their contributions over the years. I would like to thank Sam's replacement as Head of Revalidation Operations, Tony Roche, Alina's replacement as Revalidation Support Coordinator, Ben Fritchley. Marianne Whitlam is now on maternity leave and I would like to thank her replacement, Moluk All Nakash.

B. TREASURER'S ANNUAL REPORT 2019: DR CHRIS WORTH FFPM

I am pleased to present my sixth and final report as Treasurer of the Faculty of Pharmaceutical Medicine. I would like to thank Dr Tim Crook FFPM for his diligence and support as co-member of the Finance Committee.

Financial Period – 1 January to 31 December 2018

As at 31 December 2018 FPM's total free reserves amounted to £721,901 (£720,520 at the start of the period). The current level represents approximately 5.5 months' operating costs based upon budgeted expenditure for 2019. In addition to this, a sum of £143,512 (2017: £175,369) has been designated in the year as a Tangible Fixed Asset fund and represents the net book value of those assets and is therefore not available to meet future expenditure. The trustees have designated £29,596 of free reserves (£29,596 also at the start of the year), which represents the balance of funds remaining from the Development Appeal in 2002, setting these funds aside at the trustees' discretion for development projects. The balance of unrestricted funds £692,305 (2017: £690,924) are general funds available to fund day to day operations.

As at 31 December 2018 FPM's accounts showed an operating surplus of £17,197 before investment losses of £47,672 for the 12 months. Therefore, there was a deficit after investment losses of £30,475. The underlying position has improved with an operating surplus of £17,197 in 2018 compared to an operating deficit of £45,207 in 2017. This positive performance reflects the financial benefit of the actions FPM has taken to control expenditure, deliver efficiency improvements and increase income.

The full annual report and audited accounts for this period are available on FPM's website. If you have any questions on these please feel free to contact the new Treasure through the FPM office (fpm@fpm.or.uk).

Current Financial Year January – December 2019

In January 2019, FPM completed its third full year in our splendid headquarters in Islington, London, which we are renting over a ten-year lease. Tenants continue to sub-let the top floor of the building from us, which is space currently surplus to our requirements. FPM meetings and events continue to be held at FPM itself whenever this is possible including any revalidation appraisals previously held at serviced-offices in London.

In January 2019, the trustees approved a deficit operational budget for the year of £18,766 (including depreciation). At the time of writing, income is forecast to be in line with budget, but expenditure has exceeded the budget due to additional recruitment, governance and consultancy costs, plus the necessary development of the FPM website which was not included in the 2019 budget. During 2020, FPM will continue to provide more educational events, explore how we can enhance the experience of being a member of FPM, build on links made with new partners and continue developing a forward financial plan.

A planned programme of financial review and business development commenced during 2019 which will be expanded from 2020 onwards. The trustees will be seeking that operational costs are off-set by expanded and new income streams associated with our core activities in education and training. Overall, our income streams remain stable and our financial situation remains positive which continues to give a sound foundation for future development.

Faculty of Pharmaceutical Medicine Development Appeal Fund

The FPM is very grateful to individuals and organisations that have donated funds to support the development of FPM over its almost thirty-year history. Donations to the Development Fund are still very welcome. Members who are UK taxpayers and wishing to Gift Aid any donations or who are considering leaving a legacy to FPM are invited to contact myself or the Chief Executive for further details.

Thank You

I would like to take this opportunity to thank Dr Marcia Philbin, Chief Executive, and Sarah Davis, Head of Membership and Operations, and FPM staff colleagues for their support, and for the helpful advice of John Speed of JS2, our accountants, and of Joanna Pittman from Sayer Vincent, our Auditors. I would also particularly like to thank the FPM membership for its continuing support, advice and its varied activities which, as a charitable organisation, works to improve the health of patients and the public.

9th November 2019

C. REPORT ON PROGRESS AND ACHIEVEMENTS IN 2019: PROF TIM HIGENBOTTAM, FPM PRESIDENT

Introduction

Our full report for last year (2018) appears in the Report and Financial Statements dated 31 December 2018 which was subject to external audit and approved by the Board on 17 May 2018. This document can be found on the website and is also included with the agenda and papers for the 2019 AGM. The report below summarises the activities of FPM so far in 2019 and will be updated at the end of 2019 in preparation for the next year-end audit and reporting requirements.

2019 has been a year of change for FPM. We said a fond farewell to our long serving Chief Executive Mrs Kathryn Swanston and welcomed the new Chief Executive, Dr Marcia Philbin. Prior to Dr Philbin's appointment, Ms Sarah Davis, the Head of Membership and Operations, was the Acting Chief Executive. I and the Board of Trustees wish to specially thank Ms Davis for her stewardship of FPM during the year whilst we recruited a new Chief Executive.

I have completed my first full year as President and we have welcomed four new trustees:

- Dr Flic Gabbay (Vice-President)
- Dr Sharon McCullough
- Dr Tahir Saleem
- Professor Robert Unwin

2019 marked the 30th Anniversary of FPM and the 5th Edition of the Journal of FPM has been dedicated to reviewing the past 30 years of pharmaceutical medicine as well as exploring its future prospects. Dr Flic Gabbay and Professor Peter Stonier were two of the founders of FPM and share their reflections in the Journal via a special video.

FPM has begun implementing its strategy initiated in October 2018. The initial steps have taken the form of governance changes. Each Committee now reports directly to the Board of Trustees according to an annual calendar. Great responsibility is being given to the Chairs and senior managers. Their proposals to improve the services provided will be assessed for funding at the December Co-ordination committee. A new committee – the Strategy Oversight Committee chaired by David Jefferies will vet the proposals before they are reviewed by the board in January 2020. The Faculty has limited reserves for development and careful decision making is vital.

There will be a greater focus on the membership, the Ethics and Practice committee is taking on this responsibility. Other committees for example, will be offering more training and events that help our members with their professional and personal development. FPM is increasing its outward facing profile through responding to consultations as well as being invited to present at high profile events

Participating in these many activities that enhance the profile of FPM would not be possible without the support and contributions of our members. The FPM Board is extremely grateful to the volunteers who

generously give their time as members of committees and working parties. We also thank individuals who have made one-off contributions to the FPM Journal and our social content.

For information the current committees of FPM are the:

- Education and Standards Committee, which includes the Board of Examiners, Diploma and Certificate in Human Pharmacology (D/CHP) Examination Group and D/CHP Advisory Subcommittee
- Ethics and Practice Committee
- Policy and Communications Group, which includes the expert groups who respond to requests for specialist advice from the faculty
- Trainees' Committee
- Finance Committee

The Strategic Oversight Committee has been established with a number of senior fellows and specialist from outside the faculty to provide oversight of the FPM strategic projects and guide FPM's aims of increasing its international collaborations as well as national profile.

A summary of activities and other updates appear below with further information available on the website.

Education, Standards, Ethics and Practice

FPM continues to train new examiners, educational supervisors as well as revalidation appraisers and interested members are welcome to contact us about this. Other successes include

- The Diploma in Pharmaceutical Medicine (DPM) has been split into Cert and Dip
- Successful candidates can use DPM and CPM after their names
- 42 candidates sat the Part 1 and Part 2 of the DPM exam
- 95% of trainees and 87% of Educational Supervisors participated in GMC National Training survey of PMST
- 84% of trainees and 72% of Educational Supervisors expressed satisfaction with PMST
- 24 candidates have enrolled onto the PMST
- 14 candidates have completed the PMST programme
- 19 pharmaceutical physicians were entered onto the GMC's specialist register
- A Japanese version is also in development
- A guidance on interacting with patients is in the final stages of development and will be out for consultation shortly
- The FPM medal was reinstated and has been awarded to five worthy recipients
- The 2020 new PMST curriculum is progressing well with the purpose statement to be submitted before Christmas 2019

Policy and Communications

FPM continues to raise awareness of and advocate publicly for the science and practice of pharmaceutical medicine and the benefits that the specialty can bring to public health. In 2019 the Medical Devices expert group was established. The total number of expert groups now stands at six.

There were more than 1700 views of medical student Sam Waterson's video where he spoke about his experience of completing the UK first medical elective in pharmaceutical medicine. He spent 5 weeks working in the pharmaceutical industry and gained an appreciation of how the industry now recognises the importance of patient experience and the use of new technology such as genomics to develop new drug targets.

Other successes include

- Responding to media requests on Brexit and the supply of medicines
- Conversation evening on Trust and Transparency
- Education day focused on the theme "Patients in the practice of pharmaceutical medicine"
- 25% year-on-year increase in website traffic
- 40% annual increase in LinkedIn page followers to 3,400
- Excellent engagement metrics on 'meet the expert' LinkedIn posts
- More than 1700 views of medical student Sam Waterson's video where he spoke about his experience of completing the UK's first medical elective in pharmaceutical medicine
- Lead sponsorship and exhibitor spaces for Annual Symposium sold out
- Annual Symposium will take place on 14 November 2019 on the theme "Clinical research and life cycle management: shaping the future"

Specific objectives for 2019

In our annual report for 2018 we highlighted some specific objectives that we were going to pursue in 2019 and an update on these is as follows:

A consultation and launch of 'Engaging with the pharmaceutical industry and what this means for clinicians'
This resource is being developed for healthcare professionals to be able to better understand and deal with the potential interactions they may have with the life sciences industry, from liaising with sales representatives to attending conferences and giving scientific advice. Following preliminary consultation with the AoMRC, RCP, RCGP and other bodies, we are revising the initial draft and expect to publish the final version in Q1-Q2 2020 and will be seeking endorsement by external stakeholders.

The revision and relaunch of 'Good Pharmaceutical Medical Practice'

The second version of GPMP has been revised and is currently under internal review and will be issued for consultation. It will be launched in early 2020. A Japanese version is also under development.

The development and launch of a new FPM website with enhanced functionality and which will be mobile responsive

Our fantastic new 'shop window' is almost ready to launch. It will allow us to deliver our messages in a way that is not only a lot more visually appealing, but also fit for the modern internet age, with accessibility built-in, mobile optimisation, and enhanced search engine optimisation to help us grow our audience.

Explore how to broaden the medical student curriculum on medicines development beyond the Brighton and Sussex Medical School to include other medical schools

A partnership between the Brighton and Sussex Medical School, Association of the British Pharmaceutical Industry, and the Faculty of Pharmaceutical Medicine has introduced into the medical undergraduate curriculum a course on the development and regulation of medicines. The programme is geared towards equipping medical students with knowledge, skill and behaviour appropriate for prescribing medicines, drug safety reporting and an ethical interaction with the pharmaceutical industry. This programme utilises a spiral curriculum approach where medical students receive education throughout their undergraduate years of study. It provides guidance on their safe and effective use of medicines. Launched in 2019, it is planned to continue, the Medical Schools Council expressed interest and seven Medical schools have asked for further information which will be organised this coming new year.

Highlight the critical and exciting role of the First into Man Principal Investigators in medicines development and to revise the Curriculum for the Diploma of Human Pharmacology

An Advisory committee was re-constituted to revise Curriculum for the Diploma of Human Pharmacology (DHP). The purpose of the DHP training and examination is to enable doctors practising in a clinical pharmacology unit and undertaking First into Human studies of new medicines/procedures to document competence to act independently as the principal investigator (PI) in these studies. This is a critical step in the development of all new medicines and the UK currently leads in Europe with about 40% of all studies. Discussions have been held with the MHRA and the GMC as to how best optimize the training. The Clinical Pharmacology Skills Alliance (CPSA), of which we are a member, has lent significant support to our task. It has been agreed that a Certificate of Human Pharmacology will be awarded to candidates who successfully pass the first part of the DHP. Candidates who pass both papers and have successfully completed the training courses and their associated assignments and examinations, will be awarded the DHP.

Explore how to support our members' engagement in the digital future of healthcare which seeks to make the most of innovative technologies such as genomics, digital medicine, artificial intelligence and robotics to improve services

The Medical Devices expert group has been established. The UK market for medical devices is valued at around \$10.7 billion and is set to expand rapidly over the coming years. The expert group will provide a platform for physicians working in these sectors, and pharmaceutical physicians increasingly working with medical software and AI so that they can feed into policy developments as well as consider the potential impact of medical devices on patient experience and patient safety.

Thank You

Finally, once again FPM would like to extend thanks to all our members who have contributed to our activities this year, whether as committee members, specialty advisers, educational supervisors, appraisers, examiners or by supporting raising awareness and advocacy events and policy projects. We truly value your participation and support.

Faculty of Pharmaceutical Medicine
19 Angel Gate
326a City Road
London
EC1V 2PT

Tel: +44 (0)20 3696 9040

Email: fpm@fpm.org.uk

www.fpm.org.uk

Twitter: @FacultyPharmMed

Registered in England and Wales as a Charity (No. 1130573) and a Company (No. 6870644)